Wai Chun Bio-Technology Limited (Wai Chun Biotec) submitted its monthly return to Hong Kong Exchanges and Clearing for the period ended 31 October 2026, confirming stable issued share capital and outlining sizeable potential dilution from outstanding convertible bonds.

Authorised and Registered Capital • Ordinary shares: 10.00 billion authorised at HKD 0.01 par value, unchanged at HKD 100.00 million. • Convertible preference shares: 204.00 million authorised at HKD 0.01 par value, unchanged at HKD 2.04 million. • Combined authorised capital totals HKD 102.04 million.

Issued Shares and Public Float • Issued ordinary shares remained at 384.31 million, with no treasury shares held or cancelled during October. • The company affirmed compliance with the Main Board’s minimum 25% public-float requirement.

Equity-Linked Instruments 1) Share Option Scheme (adopted 22 July 2015) – Outstanding options: 15.95 million at an exercise price of HKD 0.25, exercisable until 26 June 2030. – No option exercises or share transfers occurred in October.

2) Convertible Bonds – Four tranches outstanding with an aggregate principal of HKD 102.05 million. – Conversion prices: HKD 0.06 for three tranches maturing 31 December 2027 and HKD 0.07 for a tranche maturing 21 November 2028. – Full conversion would permit issuance of up to 1.67 billion new ordinary shares—approximately 4.3 times the current share base of 384.31 million.

No warrants, additional share agreements, treasury share movements, or Hong Kong Depositary Receipts were reported for the month.

The filing was authorised by Executive Director Lam Ka Chun and attests compliance with all applicable listing and regulatory requirements.